Rege Nephro, a pioneering clinical-stage biotech company founded in 2019, has successfully raised $17 million in a recent funding round, marking a significant milestone in its mission to combat chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD). With over 13 million individuals grappling with CKD in Japan alone—340,000 of whom endure the burdensome reality of artificial dialysis—Rege Nephro's innovative approach is both timely and essential. The debilitating healthcare costs associated with dialysis reach a staggering $12 billion, accounting for 4% of Japan's total healthcare expenses, highlighting the critical need for effective and curative treatment options. Unlike existing therapies that merely manage symptoms, Rege Nephro is at the forefront of developing cell therapy utilizing nephron progenitor cells differentiated from induced pluripotent stem (iPS) cells, with the potential to regenerate kidney function. The new funding will be instrumental in advancing their groundbreaking research and clinical trials, aimed at delivering breakthrough therapies that could transform the lives of CKD patients and alleviate the significant healthcare burden resulting from the disease. As the company propels forward, it remains steadfast in its commitment to leading innovation in renal therapies, creating hope for millions affected by kidney diseases and shifting the paradigm towards a future where curative treatments are within reach.
Revolutionizing Kidney Disease Treatment: Rege Nephro Secures $17M in Series B Funding
Get the full Rege Nephro company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. The company is based on prominent international research from leading universities and funded by top Norwegian tech investors.
$10.8M Grant
today
1Security
AI & Permission Safety for Microsoft 365
$500.0K Seed
today
Daftcode
Daftcode is a Polish venture builder company. We develop tech startups, based on our ideas, research and know-how. On repeat. We co-founded and invested in numerous businesses serving customers worldwide. They include, among others: Nethone (data-driven fraud prevention solution), Elympics (full package for web3 games), Skriware (STEAM education), Oxla (world’s fastest distributed database), Booksy (booking system for health & beauty services) and many more. Follow us to stay updated with Daftcode news. Connect with us if you want to get to know us better, talk about growing your business or if you're looking for career opportunities! Join the (ad)venture!
$2.2M Seed
today
Gaius-Lex
Gaius-Lex - the AI platform for European law firms. Agent Gaius doesn't suggest. It does the work: Reads case files and contracts Finds case law that matches the facts in front of you Verifies citations, references, and sources Drafts summaries and first versions of legal documents Anonymises personal data Reviews contracts for unfair clauses and risks Tasks that take your firm hours - or full days - Agent finishes in minutes. Built for European jurisdictions Each jurisdiction we support comes with native legal sources, case law from supreme and administrative courts, and models trained to understand the local legal language - not translated, not approximated. Live today: Poland, Czechia Coming soon: Germany, Austria In the pipeline: further European jurisdictions Security without compromise Your data belongs to you. We don't train on it. We don't share it. You choose the deployment model: SaaS - ready from day one, hosted in Europe On-premise - on your firm's own infrastructure, with no client data leaving your servers Gaius-Lex is not a chatbot. It's not a search engine. It's a tool that does the actual work of a lawyer.
$502.0K Seed
today
uniperks
uniperks is a platform that connects 100+ global and polish brands with more than 300 000 verified students. ? Our mission is to support students throughout their academic journey by facilitating access to products and services that make daily life easier, more affordable, and more inspiring. ? By doing that, we help 100+ leading brands like Samsung, Google, H&M, Sephora and Nike reach real, verified students through secure university integrations, personalized campaigns, and data-driven communication. Together, we create spaces where brands genuinely add value to student life, earning loyalty through relevance, transparency, and real connection.
$100.0K Unknown
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Drover United Kingdom | Series b | $25.7M | today |
| 2 |  Boozt Denmark | Series b | $23.0M | today |
| 3 |  Workday Peakon Employee Voice United States | Series b | $35.0M | today |
| 4 |  Soluto Israel | Series b | $10.5M | today |
| 5 |  Grand Games Turkey | Series b | $70.0M | today |